3rd Quarter - Report

NVG, LLC for PHRMA

Period 3rd Quarter 2019 Filed Oct 21, 2019 Signed by Irene Bueno

Official filing
Firm
NVG, LLC
Client
PHRMA
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Intellectual property, data exclusivity and patent eligibility, generally; CREATES Act of 2019 (S.340)/(H.R.965); Preserve Access to Affordable Generics and Biosimilars Act (S.64)/(H.R.2375); Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S.1224)/(H.R.2374); Affordable Prescriptions for Patients Act (S.1416); Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act (H.R. 3991); Affordable Prescriptions for Patients Through Promoting Competition Act (H.R. 4398); Protecting Consumer Access to Generic Drugs Act (H.R. 1499).

LobbyistCovered position, as disclosed
ANDREA LARUE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 965 (116th), S. 1416 (116th), H.R. 2375 (116th), H.R. 2374 (116th), S. 64 (116th), S. 1224 (116th), H.R. 4398 (116th), S. 340 (116th), H.R. 1499 (116th), H.R. 3991 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.